1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 28, 11/Jul/2024
  4. Article
Research Open Access
Like 0
Download

Abstract

Background

As Ireland prepared for an autumn 2023 COVID-19 vaccination booster campaign, there was concern that vaccine fatigue would affect uptake, which has been abating.

Aim

This study aimed to quantify the direct impact of the COVID-19 vaccination programme in Ireland on averted COVID-19-related outcomes including symptomatic presentations to primary care/community testing centres, emergency department (ED) presentations, hospitalisations, intensive care unit (ICU) admissions and deaths, in individuals aged ≥ 50 years, during Omicron dominance.

Methods

We conducted a retrospective observational COVID-19 vaccine impact study in December 2021–March 2023 in Ireland. We used national data on notified outcomes and vaccine coverage, as well as vaccine effectiveness (VE) estimates, sourced from the World Health Organization’s live systematic review of VE, to estimate the count and prevented fraction of outcomes in ≥ 50-year-olds averted by the COVID-19 vaccination programme in this age group.

Results

The COVID-19 vaccination programme averted 48,551 symptomatic COVID-19 presentations to primary care/community testing centres (36% of cases expected in the absence of vaccination), 9,517 ED presentations (53% of expected), 102,160 hospitalisations (81% of expected), 3,303 ICU admissions (89% of expected) and 15,985 deaths (87% of expected).

Conclusions

When Omicron predominated, the COVID-19 vaccination programme averted symptomatic and severe COVID-19 cases, including deaths due to COVID-19. In line with other international vaccine impact studies, these findings emphasise the benefits of COVID-19 vaccination for population health and the healthcare system and are relevant for informing COVID-19 booster vaccination programmes, pandemic preparedness and communicating the reason for and importance of COVID-19 vaccination in Ireland and internationally.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.28.2300697
2024-07-11
2024-07-15
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.28.2300697
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/28/eurosurv-29-28-6_MARRON.html?itemId=/content/10.2807/1560-7917.ES.2024.29.28.2300697&mimeType=html&fmt=ahah

References

  1. Department of Health. Strategic Approach for the Management of COVID-19 Preparedness for Autumn/Winter 2022/2023. Ireland: Department of Health; 2022.
  2. World Health Organization (WHO). Strategy considerations for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the WHO European Region during autumn and winter 2022/23. Geneva: WHO; 2022.
  3. Health Protection Surveillance Centre (HPSC). Summary of COVID-19 virus variants in Ireland, July 2023. Ireland: HPSC; 2023.
  4. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. , COVID-19 Genomics UK (COG-UK) consortium. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12.  https://doi.org/10.1016/S0140-6736(22)00462-7  PMID: 35305296 
  5. Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022;22(7):1002-10.  https://doi.org/10.1016/S1473-3099(22)00146-3  PMID: 35405090 
  6. National Immunisation Advisory Committee (NIAC). NIAC Immunisation Guidelines: Chapter 5a COVID-19. Ireland: Royal College of Physicians of Ireland; 2023.
  7. Government of Ireland. National COVID-19 Vaccination Programme: Strategy. Ireland: Government of Ireland; 2020.
  8. European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. Stockholm: ECDC; 2023.
  9. Health Protection Surveillance Centre (HPSC). COVID-19 Vaccination Uptake in Ireland Weekly Report: Week 2 2022. Ireland: HPSC; 2022.
  10. National Immunisation Advisory Committee. Additional COVID-19 booster vaccination. Ireland: Royal College of Physicians of Ireland; 2022.
  11. European Centre for Disease Prevention and Control (ECDC). Preliminary public health considerations for COVID-19 vaccination strategies in the second half of 2022. Stockholm: ECDC; 2022.
  12. European Centre for Disease Prevention and Control (ECDC). Interim public health considerations for COVID-19 vaccination roll-out during 2023. Stockholm: ECDC; 2023.
  13. Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N Engl J Med. 2023;388(8):764-6.  https://doi.org/10.1056/NEJMc2215471  PMID: 36734847 
  14. Arbel R, Peretz A, Sergienko R, Friger M, Beckenstein T, Duskin-Bitan H, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis. 2023;23(8):914-21.  https://doi.org/10.1016/S1473-3099(23)00122-6  PMID: 37062302 
  15. Health Service Executive (HSE) National Immunisation Office. Table of recommended groups for COVID-19 autumn booster and flu vaccine. Ireland: HSE; 2023.
  16. Health Protection Surveillance Centre (HPSC). COVID-19 Vaccination Uptake in Ireland Weekly Report: Week 24 2023. Ireland: HPSC; 2023.
  17. Health Protection Surveillance Centre (HPSC). COVID-19 Vaccination Uptake in Ireland Weekly Report: Week 16 2023. Ireland: HPSC; 2023.
  18. Machado A, Kislaya I, Larrauri A, Matias Dias C, Nunes B. Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population. BMC Public Health. 2019;19(1):1690.  https://doi.org/10.1186/s12889-019-7958-8  PMID: 31842831 
  19. Sacco C, Mateo-Urdiales A, Petrone D, Spuri M, Fabiani M, Vescio MF, et al. , Italian Integrated Surveillance of COVID-19 study group. Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January-September 2021. Euro Surveill. 2021;26(47):2101001.  https://doi.org/10.2807/1560-7917.ES.2021.26.47.2101001  PMID: 34823637 
  20. Meslé MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Euro Surveill. 2021;26(47):2101021.  https://doi.org/10.2807/1560-7917.ES.2021.26.47.2101021  PMID: 34823641 
  21. Health Service Executive (HSE). Winter Plan October 2022-March 2023. Ireland: HSE; 2022.
  22. International Vaccine Access Centre Johns Hopkins Bloomberg School of Public Health and World Health Organisation (WHO) and Coalition for Epidemic Preparedness Innovations. Results of COVID-19 Vaccine Effectiveness & Impact Studies: An Ongoing Systematic Review: Methods. Geneva: WHO; 2023.
  23. VIEW-Hub. Available from: https://view-hub.org/resources
  24. Solante R, Alvarez-Moreno C, Burhan E, Chariyalertsak S, Chiu NC, Chuenkitmongkol S, et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. Expert Rev Vaccines. 2023;22(1):1-16.  https://doi.org/10.1080/14760584.2023.2143347  PMID: 36330971 
  25. Central Statistics Office (CSO). Preliminary Census 2022 results. Dublin: CSO; 2022.
  26. R Core Team. (2013). A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
  27. Tamandjou Tchuem CR, Auvigne V, Vaux S, Montagnat C, Paireau J, Monnier Besnard S, et al. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. Vaccine. 2023;41(13):2280-8.  https://doi.org/10.1016/j.vaccine.2023.02.062  PMID: 36870880 
  28. Kirsebom FCM, Andrews N, Sachdeva R, Stowe J, Ramsay M, Lopez Bernal J. Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England. Nat Commun. 2022;13(1):7688.  https://doi.org/10.1038/s41467-022-35168-7  PMID: 36509743 
  29. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1526-30.  https://doi.org/10.15585/mmwr.mm7148e1  PMID: 36454688 
  30. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-45.  https://doi.org/10.15585/mmwr.mm7104e3  PMID: 35085224 
  31. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255-63.  https://doi.org/10.15585/mmwr.mm7107e2  PMID: 35176007 
  32. Natarajan K, Prasad N, Dascomb K, Irving SA, Yang DH, Gaglani M, et al. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):495-502.  https://doi.org/10.15585/mmwr.mm7113e2  PMID: 35358170 
  33. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Xie F, et al. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. Lancet Respir Med. 2023;11(2):176-87.  https://doi.org/10.1016/S2213-2600(22)00354-X  PMID: 36216013 
  34. Link-Gelles R, Levy ME, Gaglani M, Irving SA, Stockwell M, Dascomb K, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(29):931-9.  https://doi.org/10.15585/mmwr.mm7129e1  PMID: 35862287 
  35. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379:e072141.  https://doi.org/10.1136/bmj-2022-072141  PMID: 36191948 
  36. Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023;6(3):e232598.  https://doi.org/10.1001/jamanetworkopen.2023.2598  PMID: 36920396 
  37. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis. 2022;22(12):1663-5.  https://doi.org/10.1016/S1473-3099(22)00692-2  PMID: 36306800 
  38. Bozio CH, Butterfield KA, Briggs Hagen M, Grannis S, Drawz P, Hartmann E, et al. Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance. J Infect Dis. 2023;227(12):1348-63.  https://doi.org/10.1093/infdis/jiad040  PMID: 36806690 
  39. Baum U, Poukka E, Leino T, Kilpi T, Nohynek H, Palmu AA. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. BMC Infect Dis. 2022;22(1):816.  https://doi.org/10.1186/s12879-022-07814-4  PMID: 36335289 
  40. Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Fafard J, et al. Prior infection- and/or vaccine-induced protection against Omicron BA.1, BA.2 and BA.4/BA.5-related hospitalisations in older adults: a test-negative case-control study in Quebec, Canada. medRxiv: the preprint server for health sciences. 2022:2022.12.21.22283740.  https://doi.org/10.1101/2022.12.21.22283740  https://doi.org/10.1101/2022.12.21.22283740 
  41. Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. Nat Commun. 2022;13(1):5736.  https://doi.org/10.1038/s41467-022-33378-7  PMID: 36180428 
  42. Sharma A, Oda G, Holodniy M. Effectiveness of Messenger RNA-based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. Clin Infect Dis. 2022;75(12):2186-92.  https://doi.org/10.1093/cid/ciac325  PMID: 35475889 
  43. Wan EYF, Mok AHY, Yan VKC, Chan CIY, Wang B, Lai FTT, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. J Travel Med. 2022;29(8):taac119.  https://doi.org/10.1093/jtm/taac119  PMID: 36250571 
  44. Young-Xu Y, Zwain GM, Izurieta HS, Korves C, Powell EI, Smith J, et al. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. BMJ Open. 2022;12(8):e063935.  https://doi.org/10.1136/bmjopen-2022-063935  PMID: 35922100 
  45. Gram MA, Emborg HD, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. PLoS Med. 2022;19(9):e1003992.  https://doi.org/10.1371/journal.pmed.1003992  PMID: 36048766 
  46. Kislaya I, Machado A, Magalhães S, Rodrigues AP, Franco R, Leite PP, et al. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022. Euro Surveill. 2022;27(37):2200697.  https://doi.org/10.2807/1560-7917.ES.2022.27.37.2200697  PMID: 36111555 
  47. Yan VKC, Wan EYF, Ye X, Mok AHY, Lai FTT, Chui CSL, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study. Emerg Microbes Infect. 2022;11(1):2304-14.  https://doi.org/10.1080/22221751.2022.2114854  PMID: 35980089 
  48. Park SK, Choe YJ, Jang EJ, Kim RK, Lee SW, Kwon GY, et al. Effectiveness of Heterologous COVID-19 Vaccine Booster in Korean Elderly Population, 2022. J Korean Med Sci. 2023;38(19):e143.  https://doi.org/10.3346/jkms.2023.38.e143  PMID: 37191847 
  49. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021;21(11):1529-38.  https://doi.org/10.1016/S1473-3099(21)00289-9  PMID: 34174193 
  50. Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R, et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. Lancet Reg Health West Pac. 2023;40:100928.  https://doi.org/10.1016/j.lanwpc.2023.100928  PMID: 37854458 
  51. Stamm TA, Partheymüller J, Mosor E, Ritschl V, Kritzinger S, Alunno A, et al. Determinants of COVID-19 vaccine fatigue. Nat Med. 2023;29(5):1164-71.  https://doi.org/10.1038/s41591-023-02282-y  PMID: 36973410 
  52. Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, d’Andrea V, et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(5):e2310650.  https://doi.org/10.1001/jamanetworkopen.2023.10650  PMID: 37133863 
  53. European Centre for Disease Prevention and Control (ECDC). Country overview report: week 31 2023. Stockholm: ECDC; 2023.
  54. McKeown D, McCourt A, Hendrick L, O’Farrell A, Donohue F, Grabowsky L, et al. COVID-19 incidence and outcome by affluence/deprivation across three pandemic waves in Ireland: A retrospective cohort study using routinely collected data. PLoS One. 2023;18(7):e0287636.  https://doi.org/10.1371/journal.pone.0287636  PMID: 37478117 
  55. Department of Health and Health Service Executive. Impact of COVID on the health service. Ireland: Department of Health; 2021.
  56. Health Service Executive (HSE). National Adult Critical Care Capacity - Census 2021 Report. Ireland: HSE; 2021.
  57. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293-302.  https://doi.org/10.1016/S1473-3099(22)00320-6  PMID: 35753318 
The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Louise+Marron&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Marron Louise</a>, <a href="/search?value1=Alberto+Mateo-Urdiales&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mateo-Urdiales Alberto</a>, <a href="/search?value1=Joan+O%E2%80%99Donnell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">O’Donnell Joan</a>, <a href="/search?value1=Eve+Robinson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Robinson Eve</a>, <a href="/search?value1=Lisa+Domegan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Domegan Lisa</a></span>. The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(28):pii=2300697. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.28.2300697" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.28.2300697</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 05 Dec 2023;&nbsp;&nbsp; <span class="generated">Accepted</span>: 04 Mar 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.28.2300697
/content/10.2807/1560-7917.ES.2024.29.28.2300697
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error